2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

4:30PM-6:00PM: Abstract Number: 1913

Associations of HLA-B Alleles, Enthesitis and Peripheral Arthritis in Ankylosing Spondylitis

4M121: Spondyloarthritis Including Psoriatic Arthritis – Clinical IV: Axial Spondyloarthritis Translational Research (1908–1913)

4:30PM-6:00PM: Abstract Number: 1884

Autoantibodies to Malondialdehyde-acetaldehyde Preceding the Diagnosis of Rheumatoid Arthritis

4M116: RA – Diagnosis, Manifestations, & Outcomes III: Diagnosis & Prognosis (1884–1889)

4:30PM-6:00PM: Abstract Number: 1880

Baricitinib 4 Mg and 2 Mg Once Daily Reduced Pain in Both Patients Who Were Opioid Users and Non-users in Active Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3 Trials

4M115: Pain Mechanisms – Basic & Clinical Science (1878–1883)

4:30PM-6:00PM: Abstract Number: 1858

Beta-2-Glycoprotein-I IgA Antibodies Predict Coronary Plaque Burden, Progression and Moderate the Effect of Inflammation on Atherosclerosis in Rheumatoid Arthritis

4M111: Imaging of Rheumatic Diseases I (1854–1859)

4:30PM-6:00PM: Abstract Number: 1895

Biologics Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Non-calcified Coronary Plaque Progression and Stabilizing Vulnerable Plaques

4M117: RA – Treatments III: Cardiovascular Disease & Readmissions (1890–1895)

4:30PM-6:00PM: Abstract Number: 1889

Biomarkers of Clinical Relapse and Radiological Progression in Patients with Rheumatoid Arthritis in Remission: Observational Study of 5 Years of Follow-up

4M116: RA – Diagnosis, Manifestations, & Outcomes III: Diagnosis & Prognosis (1884–1889)

4:30PM-6:00PM: Abstract Number: 1867

Body Composition in Myositis Patients Is Negatively Changed Compared to Healthy Controls and the Changes Are Associated with Disease Activity and Duration, Skeletal Muscle Involvement and Physical Activity and Nutritional Status

4M113: Muscle Biology, Myositis & Myopathies I (1866–1871)

4:30PM-6:00PM: Abstract Number: 1896

Breastfeeding in Women with Rheumatic Diseases

4M118: Reproductive Issues in Rheumatic Disorders (1896–1901)

4:30PM-6:00PM: Abstract Number: 1903

BTK Overexpression Is Associated with the Risk of Lymphoma in Primary Sjögren’s Syndrome: Data from Whole Blood Transcriptome of 346 Patients Followed-up Prospectively for 10 Years

4M119: Sjögrenʼs Syndrome – Basic & Clinical Science (1902–1907)

4:30PM-6:00PM: Abstract Number: 1868

Clinical Correlations of Autoantibodies Against Heat Shock Cognate 71 kDa Protein in Patients with Juvenile Dermatomyositis

4M113: Muscle Biology, Myositis & Myopathies I (1866–1871)

4:30PM-6:00PM: Abstract Number: 1852

Community-level Deprivation Index: Impact on Discharge Destination After Elective Hip Replacement

4M110: Healthcare Disparities in Rheumatology (1848–1853)

4:30PM-6:00PM: Abstract Number: 1849

Cost-related Prescription Non-adherence Is Associated with Patient-reported Outcomes of Systemic Lupus Erythematosus Activity and Damage: The Michigan Lupus Epidemiology & Surveillance (MILES) Cohort

4M110: Healthcare Disparities in Rheumatology (1848–1853)

4:30PM-6:00PM: Abstract Number: 1919

Development of a Multi-Modality Imaging Approach to Evaluate Lupus Nephritis

4M120: SLE – Clinical IV: Lupus Nephritis (1914–1919)

4:30PM-6:00PM: Abstract Number: 1923

Disability and Health-Related Quality of Life Outcomes in Patients with Systemic or Polyarticular Juvenile Idiopathic Arthritis Treated with Tocilizumab in Randomized Controlled Phase 3 Trials

4M125: Pediatric Rheumatology: Outcomes & Quality of Life (1920–1925)

4:30PM-6:00PM: Abstract Number: 1925

Discriminant and Predictive Ability of the Parent Version of the Juvenile Arthritis Disease Activity Score in Two Large Multination Cohorts of Patients with Juvenile Idiopathic Arthritis

4M125: Pediatric Rheumatology: Outcomes & Quality of Life (1920–1925)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].